Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fenglong Xie

Showing results (1-10 of 124) with videos related to

Pageof 13
Sort By:
Journal of Scleroderma and Related Disorders|April 6, 2022
Assessing the prevalence of juvenile systemic sclerosis in childhood using administrative claims data from the United StatesTimothy Beukelman, Fenglong Xie, Ivan Foeldvari
Journal of Scleroderma and Related Disorders|April 6, 2022
The prevalence of localised scleroderma in childhood assessed in the administrative claims data from the United StatesTimothy Beukelman, Fenglong Xie, Ivan Foeldvari
ACR Open Rheumatology|July 16, 2022
Investigation of Inactive Disease States Among Patients With Juvenile Idiopathic Arthritis in the Childhood Arthritis and Rheumatology Research Alliance RegistryMelissa L Mannion, Fenglong Xie, Timothy Beukelman, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|February 14, 2018
ReplyFenglong Xie, Lang Chen, Huifeng Yun, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|May 24, 2016
Brief Report: Risk of Gastrointestinal Perforation Among Rheumatoid Arthritis Patients Receiving Tofacitinib, Tocilizumab, or Other Biologic TreatmentsFenglong Xie, Huifeng Yun, Sasha Bernatsky, et al.
Arthritis Research & Therapy|December 14, 2019
Will savings from biosimilars offset increased costs related to dose escalation? A comparison of infliximab and golimumab for rheumatoid arthritisJeffrey R Curtis, Fenglong Xie, Jonathan Kay, et al.
Arthritis Care & Research|January 22, 2026
Use of a Molecular Signature Response Classifier to Inform Treatment Selection Improves Clinical Disease Activity Among Patients with Rheumatoid Arthritis Initiating a Biologic or Targeted Synthetic Disease-modifying Antirheumatic DrugFenglong Xie, Timothy Beukelman, Nicholas P McCormick, et al.
The Journal of Rheumatology|August 3, 2014
Recent trends in medication usage for the treatment of juvenile idiopathic arthritis and the influence of tumor necrosis factor inhibitorsMelissa L Mannion, Fenglong Xie, Jeffrey R Curtis, et al.
Pharmacoepidemiology and Drug Safety|June 22, 2023
Identifying inpatient mortality in MarketScan claims data using machine learningFenglong Xie, Timothy Beukelman, Dongmei Sun, et al.
Arthritis Research & Therapy|October 16, 2020
Use of ICD-10 diagnosis codes to identify seropositive and seronegative rheumatoid arthritis when lab results are not availableJeffrey R Curtis, Fenglong Xie, Hong Zhou, et al.
Pageof 13

Showing results (1-10 of 124) with videos related to

Sort By:
Pageof 13
Journal of Scleroderma and Related Disorders|April 6, 2022
Assessing the prevalence of juvenile systemic sclerosis in childhood using administrative claims data from the United StatesTimothy Beukelman, Fenglong Xie, Ivan Foeldvari
Journal of Scleroderma and Related Disorders|April 6, 2022
The prevalence of localised scleroderma in childhood assessed in the administrative claims data from the United StatesTimothy Beukelman, Fenglong Xie, Ivan Foeldvari
ACR Open Rheumatology|July 16, 2022
Investigation of Inactive Disease States Among Patients With Juvenile Idiopathic Arthritis in the Childhood Arthritis and Rheumatology Research Alliance RegistryMelissa L Mannion, Fenglong Xie, Timothy Beukelman, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|February 14, 2018
ReplyFenglong Xie, Lang Chen, Huifeng Yun, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|May 24, 2016
Brief Report: Risk of Gastrointestinal Perforation Among Rheumatoid Arthritis Patients Receiving Tofacitinib, Tocilizumab, or Other Biologic TreatmentsFenglong Xie, Huifeng Yun, Sasha Bernatsky, et al.
Arthritis Research & Therapy|December 14, 2019
Will savings from biosimilars offset increased costs related to dose escalation? A comparison of infliximab and golimumab for rheumatoid arthritisJeffrey R Curtis, Fenglong Xie, Jonathan Kay, et al.
Arthritis Care & Research|January 22, 2026
Use of a Molecular Signature Response Classifier to Inform Treatment Selection Improves Clinical Disease Activity Among Patients with Rheumatoid Arthritis Initiating a Biologic or Targeted Synthetic Disease-modifying Antirheumatic DrugFenglong Xie, Timothy Beukelman, Nicholas P McCormick, et al.
The Journal of Rheumatology|August 3, 2014
Recent trends in medication usage for the treatment of juvenile idiopathic arthritis and the influence of tumor necrosis factor inhibitorsMelissa L Mannion, Fenglong Xie, Jeffrey R Curtis, et al.
Pharmacoepidemiology and Drug Safety|June 22, 2023
Identifying inpatient mortality in MarketScan claims data using machine learningFenglong Xie, Timothy Beukelman, Dongmei Sun, et al.
Arthritis Research & Therapy|October 16, 2020
Use of ICD-10 diagnosis codes to identify seropositive and seronegative rheumatoid arthritis when lab results are not availableJeffrey R Curtis, Fenglong Xie, Hong Zhou, et al.
Pageof 13